Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS ® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS ® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Synchrony Financial (SYF) Reports Strong Earnings Growth Despite Share Buyback Completion
Synchrony Financial recently reported second-quarter earnings, showcasing a rise in net interest income to $4,521 million from the previous year, alongside an improved net income of $967 million. This announcement, combined with declared dividends and a completed share buyback plan repurchasing 2.25% of outstanding shares, likely supported the company's stock surge of 43% over the last quarter. This performance contrasts with broader market trends where the S&P 500 and Nasdaq peaked then slightly retreated amid varied corporate earnings. Synchrony Financial's initiatives and financial results may have thus contributed to its distinct price movement within the prevailing market landscape. We've identified 2 weaknesses with Synchrony Financial and understanding the impact should be part of your investment process. Rare earth metals are the new gold rush. Find out which 26 stocks are leading the charge. The recent boost in Synchrony Financial's net interest income and net income, in conjunction with its completed share repurchase plan, underscores potential alignment with the narrative of strengthening its financial position through diligent capital management. This ties in with the company's focus on enhancing customer loyalty and increasing purchase volume through partnerships and new card offerings, which could support future revenue growth despite previously observed challenges in purchase volume and liquidity yields. Over the past five years, Synchrony Financial's total return surged 231.17%, reflecting significant long-term shareholder value appreciation. In comparison to the recent one-year period, the company outperformed both the US market and the Consumer Finance industry, which recorded returns of 14.8% and 30.8% respectively. Such performance highlights Synchrony Financial's resilience and effective strategies amidst fluctuating market conditions. In light of the recent news, analysts' forecasts for revenue growth of 23.8% annually over the next three years could be further supported by Synchrony's ability to maintain strong capital positions through share buybacks and dividends, enhancing its net interest income. However, a shrinkage in profit margins to 20.1% could temper earnings growth expectations, impacting the anticipated increase to $3.3 billion by 2028. The current share price of $69.44, trading at an 11.6% discount from the US$77.5 price target, suggests potential future appreciation if the company successfully navigates its growth catalysts. Assess Synchrony Financial's previous results with our detailed historical performance reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SYF. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
16 minutes ago
- Yahoo
IQVIA Holdings (IQV) Updates 2025 Revenue Guidance and Completes Share Buyback
IQVIA Holdings recently updated its earnings guidance for 2025 with expectations of revenue ranging between $16,100 million and $16,300 million. This update coincides with the company's Q2 earnings announcement, showing an increase in sales to $4,017 million but a decline in net income to $266 million. During the last quarter, IQVIA's share price rose 11%, likely supported by its ongoing share buyback program, where the company repurchased 3,985,000 shares. Despite the broader market fluctuations amid record highs reached by the S&P 500 and Nasdaq, IQVIA's proactive measures appear aligned with its recent share price uptick. We've discovered 1 weakness for IQVIA Holdings that you should be aware of before investing here. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. The recent update in IQVIA Holdings' earnings guidance and its ongoing share buyback program suggest a focused strategy to enhance shareholder value, aligning with the uptick in its share price. However, the total return including share price and dividends over the past five years shows a 2.05% decline, indicating challenges in achieving sustainable long-term growth. This performance contrasts with the broader market's one-year performance, where IQVIA underperformed the US Life Sciences industry, which itself experienced a 22% decline. The company's anticipated revenue range of US$16.1 billion to US$16.3 billion by 2025 and partnerships like those with NVIDIA could provide a cost advantage and potentially elevate margins, important factors amid macroeconomic pressures. Analysts foreseeing revenue growth of 5.2% annually over the next three years could see risks should sector funding conditions deteriorate. The current share price is below the consensus price target of US$190.67, suggesting potential for appreciation if earnings and revenue forecasts materialize as expected, though differing analyst views present varying degrees of confidence in this forecast. Understand IQVIA Holdings' track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
Rémy Cointreau: Combined General Meeting of July, 2025
PARIS, July 22, 2025--(BUSINESS WIRE)--Regulatory News: The Combined General Meeting of Rémy Cointreau (Paris:RCO) shareholders was held on July 22, 2025, in Paris, under the chairwomanship of Marie-Amélie de Leusse. Dividend distribution: The meeting approved the financial statements for the 2024-25 financial year and set the amount of the dividend at 1.5€ per share—€1.0 in cash, and €0.5 for which it decided to give each shareholder the option of receiving payment in cash or in shares. The dividends will go ex-dividend on July 28, 2025 and be paid from October 1st, 2025. Shareholders who wish to opt for the payment of the dividend in shares will have a period of time between July 30 and September 15, 2025 inclusive to make a request to their financial intermediary. Shareholders who have not exercised their options by 5 p.m. on September 15, 2025 will only be able to receive their dividends in cash. The issue price of the new share is set at €44.33. If the amount of the net dividend to which the shareholder is entitled does not equate to a whole number of shares, the shareholder may obtain the number of shares immediately above by paying the difference in cash on the day of exercising the option or receive the number of shares immediately below plus a cash balance. The new shares will be subject to all legal and statutory provisions and will carry dividend rights as from 1st April 2025, the beginning of the current financial year. They will be issued in registered or bearer form, at the shareholder's choice. Shareholders will receive a request for instructions, which they must complete and sign and return, from the financial intermediary with whom their shares are held. A request will be made for the new shares to be traded on Euronext Paris. Governance: The meeting approved the renewal, for three years, of the mandates of: Hélène Dubrule and M. Alain Li, as independent Board members Marie-Amélie de Leusse as Board members representing the reference shareholder The Company Orpar SA, a legal entity represented by Jérôme Bosc, has been appointed to the Board of Directors, replacing Marc Hériard Dubreuil, who will now serve as a non-voting Board observer (censeur). The meeting also approved the appointment of Jessica Spence, as an independent Board member for a period of three years, replacing Olivier Jolivet. His appointment will ensure a stronger representation on the Board of Directors of executives with extensive experience in the U.S. market and the Wine and Spirits industry. Following the Annual General Meeting, the Board of Directors approved the appointment of Jessica Spence to the Corporate Social and Environmental Responsibility Committee, and Alain Li to the Nominations and Compensation Committee, replacing Olivier Jolivet, who previously served on both committees. Lastly, the Board of Directors appointed Nicolas Hériard Dubreuil as a non-voting Board observer (censeur), replacing his father, François Hériard Dubreuil. The Board of Directors consists of 12 Board members and 3 non-voting members with now a feminization rate of 50% (vs. 42% previously) and independence of 58% (unchanged), in line with AFEP-MEDEF recommendations. Finally, the Annual General Meeting approved all components of executive compensation. About Rémy Cointreau All around the world, there are clients seeking exceptional experiences; clients for whom a wide range of terroirs means a variety of flavors. Their exacting standards are proportional to our expertise – the finely-honed skills that we pass down from generation to generation. The time these clients devote to drinking our products is a tribute to all those who have worked to develop them. It is for these men and women that Rémy Cointreau, a family-owned French Group, protects its terroirs, cultivates exceptional multi-centenary spirits and undertakes to preserve their eternal modernity. The Group's portfolio includes 14 singular brands, such as the Rémy Martin and LOUIS XIII cognacs, and Cointreau liqueur. Rémy Cointreau has a single ambition: becoming the world leader in exceptional spirits. To this end, it relies on the commitment and creativity of its 1,856 employees and on its distribution subsidiaries established in the Group's strategic markets. Rémy Cointreau is listed on Euronext Paris. Regulated information in connection with this press release can be found at View source version on Contacts Investor relations: Célia d'Everlange / investor-relations@ Media relations: Mélissa Lévine / press@ Sign in to access your portfolio
